NodThera
PrivateLast Round
IPO
Mar 27, 2026
Total Funding Raised
$145M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
NodThera operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series D round in April 2025.
NodThera is a biotechnology company that develops small molecule NLRP3 inflammasome inhibitors for the treatment of chronic inflammatory, cardiometabolic, and neuroinflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
NodThera Comparables
Compare NodThera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Halia Therapeutics | 91% | |
| Ventus Therapeutics | 88% | |
| Eli Lilly and Company | 86% |
For institutional investors. Book with your work email.
NodThera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Mar 27, 2026 | ||||
| Series D | Apr 1, 2025 | ||||
| Series B | Jun 3, 2020 | ||||
| Series A | Jun 25, 2018 | ||||
| Seed | Jul 28, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
NodThera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Epidarex Capital | Series D, Series A, Series B, Seed |
| F-Prime Capital | Series D, Series A, Series B |
| TD Securities | Series B |
| Blue Owl Capital | Series D, Series B |
| 5AM Ventures | Series D, Series B, Series A |
| Novo Holdings | Series D, Series B |
| Sanofi Ventures | Series D, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 113% MoM, from 1.7K to 3.7K.
- Apr 21, 2026
Clinical and commercial plan for ruvonoflast includes Phase 2 data in July 2026 and launch in early 2029.
For institutional investors. Book with your work email.
NodThera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about NodThera's valuation, stock price, and market status.
Is NodThera a public or private company?
NodThera is a private company.
What is the current stock price of NodThera?
NodThera is a private company, so its shares have no public market price. Caplight tracks NodThera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is NodThera worth (valuation)?
Valuation information for NodThera is not publicly available.
Can I buy NodThera stock?
NodThera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was NodThera's last funding round?
NodThera's most recent funding round was ipo on March 27, 2026.
Who are the main investors in NodThera?
Key investors in NodThera include Epidarex Capital, 5AM Ventures, Novo Holdings, Sofinnova Partners.
Will NodThera IPO soon?
No public IPO plans have been announced for NodThera.
How can I track NodThera secondary market activity?
Caplight tracks bids, offers, and trades in NodThera's shares on secondary markets.